Mirtastad (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which boosts the release of norepinephrine and serotonin. It also antagonizes certain serotonin receptors (5‑HT2 and 5‑HT3), shifting activity toward the 5‑HT1A pathway and enhancing mood‑regulating neurotransmission.

The appropriate dose of Mirtastad is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made during treatment to achieve the best therapeutic outcome while minimizing side effects.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative treatments when possible. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To request Mirtastad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtastad (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in pronounced sedation and appetite increase, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtastad tablets should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from excess moisture and direct sunlight to maintain stability and potency throughout the shelf life.

Mirtastad is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis or neutropenia, severe hypersensitivity reactions, and the emergence or worsening of suicidal thoughts, especially during the initial weeks of therapy. Patients should be monitored closely for signs of infection, allergic reactions, or changes in mood.

Mirtastad is contraindicated in individuals who have a known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in patients currently taking monoamine oxidase inhibitors (MAOIs) or those with uncontrolled severe hepatic impairment without appropriate dose adjustment.